ClinicalTrials.gg

Program

ZT002

A development code. Also written as “ZT002 Injection”, “ZT002 injection, metformin, warfarin” and “ZT002 injection, rosuvastatin, digoxin”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by 2 companies.

Furthest: phase 3, since Nov 13, 20259 company-led studies, 4 open or runningNext primary completion: Dec 5, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing QL Biopharmaceutical84 open or runningphase 3since Nov 13, 2025Apr 10, 2024Dec 5, 2026phase 1 · NCT07550816
QL Biopharmaceutical Australia Pty10 open or runningphase 1since Aug 1, 2022Aug 1, 2022none ahead

Also a collaborator on its studies: novotech-australia-pty-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 1, 2022First study: phase 1 study in Diabetes Mellitus, Type 2New to QL Biopharmaceutical Australia PtyQL Biopharmaceutical Australia Pty · NCT05491421 · 32 enrolled · Australia
  2. Apr 10, 2024Beijing QL Biopharmaceutical's first study: phase 1 study in OverweightNew to Beijing QL BiopharmaceuticalBeijing QL Biopharmaceutical · NCT06371326 · 28 enrolled · China
  3. May 16, 2024Phase 1 study in Diabetes Mellitus, Type 2Beijing QL Biopharmaceutical · NCT06423872 · 28 enrolled · China
  4. Jun 6, 20252 phase 2 studiesBeijing QL Biopharmaceutical · NCT07065032, NCT07020884
  5. Nov 13, 2025Phase 3 study in OverweightBeijing QL Biopharmaceutical · NCT07230119 · 755 enrolled · China
  6. Apr 20, 2026Phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816 · 60 enrolled · China
  7. Jun 29, 2026Phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07697846 · 40 enrolled · China
  8. Aug 31, 2026Phase 2 study in ObesityBeijing QL Biopharmaceutical · NCT07812597 · 210 planned · China

Ahead

  1. Dec 5, 2026Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07550816
  2. Jan 13, 2027Primary completion: phase 1 study in OverweightBeijing QL Biopharmaceutical · NCT07697846
  3. May 29, 2027Primary completion: phase 3 study in OverweightBeijing QL Biopharmaceutical · NCT07230119
  4. Jan 13, 2028Primary completion: phase 2 study in ObesityBeijing QL Biopharmaceutical · NCT07812597

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07812597Obesity · China2Not yet recruitingBeijing QL BiopharmaceuticalJan 13, 2028210
NCT07697846Overweight · China1Active, not recruitingBeijing QL BiopharmaceuticalJan 13, 202740
NCT07550816Overweight · China1Active, not recruitingBeijing QL BiopharmaceuticalDec 5, 202660
NCT07230119Overweight · China3Active, not recruitingBeijing QL BiopharmaceuticalMay 29, 2027755
NCT07065032Diabetes Mellitus, Type 2 · China2CompletedBeijing QL BiopharmaceuticalJul 22, 202427
NCT07020884Overweight · China2CompletedBeijing QL BiopharmaceuticalMay 7, 2025303
NCT06423872Diabetes Mellitus, Type 2 · China1CompletedBeijing QL BiopharmaceuticalOct 20, 202328
NCT06371326Overweight · China1CompletedBeijing QL BiopharmaceuticalApr 15, 202428
NCT05491421Diabetes Mellitus, Type 2 · Australia1CompletedQL Biopharmaceutical Australia PtyApr 28, 202332

How it is read

Names in the registry

  • “ZT002 Injection”, 4 entries
  • “ZT002”, 2 entries
  • “ZT002 injection, metformin, warfarin”, 1 entry
  • “ZT002 injection, rosuvastatin, digoxin”, 1 entry
  • “ZT002 injection”, 1 entry

Codes read as this program: ZT002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.